Ebola Deaths in Democratic Republic of Congo Exceed 5,000 in Bundibugyo Outbreak

The death toll from the Bundibugyo Ebola outbreak in the Democratic Republic of Congo surpassed 5,000 by the end of October 2026, according to government figures. Confirmed and probable cases exceeded 10,000 since the outbreak was declared in May.

This is Congo’s largest and deadliest Ebola epidemic on record and the world’s second-largest after the 2014-2016 West African outbreak that killed more than 11,000 people. The Bundibugyo species has no approved vaccine or specific treatment. Eight of Congo’s 26 provinces have reported cases: Haut-Uele, Ituri, North Kivu, South Kivu, Bas-Uele, Tshopo, South Ubangi and North Ubangi.

Many deaths have occurred outside treatment centres. Only about 12 percent of confirmed cases were identified among previously known contacts, indicating gaps in early detection and tracing. Conflict, delayed recognition and strained health services have accelerated spread compared with earlier outbreaks in the same regions.

Nigeria reported a case in late October, becoming the fourth African country affected after Kenya and Uganda. The geographic expansion into West and East Africa raises the risk of further seeding if travellers move while infectious. Africa CDC called for stronger protection of frontline workers after two Congolese doctors died in North Kivu and Ituri.

Health workers in protective equipment continue contact tracing and isolation in affected provinces. Community deaths complicate safe burial practices and increase secondary transmission. The absence of a vaccine means reliance on supportive care, infection prevention and rapid isolation once symptoms appear.

Previous Bundibugyo outbreaks have been smaller and more contained. The current epidemic’s size reflects the combination of a less familiar virus, ongoing insecurity in eastern Congo and limited laboratory capacity for rapid confirmation. Laboratories must distinguish Bundibugyo from other filoviruses that circulate in the region.

International partners have supplied personal protective equipment and laboratory reagents. Treatment centres operate in several provinces, yet occupancy and referral delays remain high. Patients who reach care early have better survival odds, but many arrive after days of community transmission.

The government and UN agencies reported signs of slowing transmission in parts of Ituri earlier in October, yet new chains continued to appear in North Kivu and newly affected western provinces. Movement of people between conflict zones and urban centres sustains the spread.

By early November the cumulative death figure stood above 5,000 with no clear peak. Daily case counts fluctuate with testing volume. The second-deadliest status relative to the West African epidemic underscores the challenge of controlling a filovirus without specific medical countermeasures in a setting of weak health infrastructure and active conflict.

Surveillance teams continue door-to-door work in high-risk zones. Safe and dignified burial protocols are enforced where possible. The outbreak’s duration, now approaching six months, has exhausted local stocks of protective gear in some districts.

Regional governments have increased screening at borders. The Nigerian case prompted additional checks at airports and land crossings. Further exportation remains possible until transmission is interrupted inside Congo.

No timeline for containment has been announced. The combination of an unvaccinated population, incomplete contact tracing and cross-border movement keeps the risk elevated into November and beyond.